Pharma’s digital media allocation up 13%: dentsu-e4m report

Pharmaceutical advertising in India is undergoing a decisive digital pivot. According to the dentsu-e4m Digital Advertising Report 2026, the sector has increased its digital media allocation from 54% to 67% of total media spends, marking one of the most significant shifts among all major industry verticals.

This jump is not incremental. It signals a structural change in how pharma brands are approaching communication, engagement, and compliance in a market increasingly shaped by search behaviour, condition-led queries, and always-on information access.

In 2025, the pharmaceutical sector accounted for ₹4,933 crore in overall advertising spends, representing 4% of total industry expenditure. Out of this, ₹3,328 crore was directed specifically towards digital media, placing pharma among the faster-growing digital adopters alongside FMCG, e-commerce, and telecom.

The report highlights that 42% of pharma’s digital budget is allocated to paid search, the highest search dependency among all sectors. This is driven by the nature of pharmaceutical discovery. Consumers and caregivers increasingly begin their journey with symptom-based or condition-specific searches. In such an environment, visibility on search platforms becomes not just a marketing tactic but a primary gateway to engagement.

Unlike FMCG or automotive, where video and storytelling dominate, pharma’s digital strategy is precision-led. Search offers accuracy, intent capture, and compliance-friendly formats that allow brands to reach users actively seeking information, without breaching regulatory sensitivities.

Online video and social media still play roles, but largely as supporting channels for awareness, education, and credibility-building. The core remains performance-led, query-driven discovery.

This evolution also reflects a broader behavioural change. Patients today are more informed, proactive, and digitally native. Health queries, treatment comparisons, and medicine awareness increasingly happen online before any offline consultation. Pharma advertising is aligning itself with this reality.

The rise in digital allocation is also aided by India’s expanding digital infrastructure. With deeper internet penetration, UPI-linked ecosystems, and ONDC-led commerce integration, the path from awareness to purchase has become measurably trackable. This suits pharmaceutical brands that operate within strict accountability frameworks.

Another key factor is measurability. Traditional media such as print and television, once dominant in pharma communication for trust-building, are witnessing a relative decline in allocation because they cannot match the attribution and targeting capabilities of digital platforms. As the report notes, sectors requiring precise targeting, measurable outcomes and always-on engagement are increasingly prioritising digital media. Pharma fits this description perfectly.

The shift from 54% to 67% digital allocation is therefore less about trend-following and more about necessity. Pharma brands are responding to how patients seek information, how regulations shape messaging formats, and how digital environments allow both reach and responsibility.

In the broader context of India’s advertising ecosystem, where digital’s share has grown from 12% in 2016 to 59% in 2025, pharma’s acceleration shows how even highly regulated sectors are embracing digital-first strategies when the medium aligns with consumer behaviour and compliance needs.

As digital media is projected to command 70% of total ad spends by 2027, pharma’s early and aggressive reallocation positions it ahead of the curve. The prescription for growth, it seems, now runs through search bars, video feeds, and measurable media journeys rather than traditional front-page placements.